Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05052242 |
Other study ID # |
Rajavithi hospital |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
May 1, 2020 |
Est. completion date |
September 3, 2021 |
Study information
Verified date |
September 2021 |
Source |
Rajavithi Hospital |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Purpose: To investigate agreement between 2 swept source OCT biometers, IOL M.aster700 and
Anterion, in various ocular biometry and intraocular lens (IOL) calculations of primary
angle-closure disease (PACD).
Methods: This was a prospective study conducted in a tertiary eye care centre involving
biometric measurements obtained with 2 devices in phakic eye with diagnosis of PACD. Mean
difference and intraclass correlation coefficient (ICC) with confidence limits were assessed,
and calculations of estimated residual refraction of the IOL were analysed using Barrett's
formula.
Description:
Primary angle-closure disease (PACD) is the leading cause of blindness worldwide. PACD is an
anatomic disorder, typically of relatively small eye with shallow anterior chamber depth
(ACD), thick lens, shorter axial length (AL), small corneal curvature, and relatively
anterior lens position. Pupillary block, plateau iris and phacomorphic mechanisms play major
roles in the pathophysiology of the disease, and pupillary block is thought to be the most
common causal mechanism.
For decades, phacoemulsification and intraocular lens implantation (PEI) has been proposed
for initial management of PACD.4 PEI relieves pupillary block, deepening ACD and widening
irido-corneal angle.
Biometry is essential in evaluating ocular dimensions and calculating IOL power in PACD, and
ocular biometers have been evolving in recent years. Optical coherence tomography (OCT)
includes partial coherence interferometry (PCI), and swept source OCT (SS-OCT) is in general
use in clinical practice. The agreement of the calculations of these devices has been studied
by many investigators; however, research into their agreement in PACD patients has been
sparse so far. A newer SS-OCT, Anterion, is now available and its performance needs to be
evaluated.